Stocks Health care EXOZ
NASDAQ · Health careExozymes Inc. (EXOZ)
It posted a net loss of $10.2M. In fiscal 2025 capital spending exceeded operating cash flow by $6.7M. At June 30, 2026 it held $5.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Exozymes Inc.
- Net worth
- Exozymes Inc. has a market value (market cap) of $39.7M at the latest share price, and shareholders' equity of $3.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $70.1K, with a net loss of $2M.
- Cash flow
- In fiscal 2025 operations used $6.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Exozymes Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Exozymes Inc. does
Exozymes Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EXOZ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$9.2M | -$1.09 | -$6.7M |
| 2024 | n/a | -$5.9M | -$0.89 | -$8.9M |
| 2024 | $70.1K | -$2M | -$0.33 | -$1.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Exozymes Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Additional proxy material DEFA14A
- September 28, 2026Proxy statement DEF 14A
- September 18, 2026Other event 8-K
- August 13, 2026
- July 1, 2026
- June 26, 2026
- June 17, 2026
- June 8, 2026
- May 14, 2026
- May 7, 2026Other event 8-K
Insider trades
What the people running Exozymes Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $6.4K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 26, 2026 | Heltzen MichaelChief Executive Officer | Bought | 4 | $30.3 |
| August 26, 2026 | Heltzen MichaelChief Executive Officer | Bought | 251 | $1.8K |
| August 26, 2026 | Heltzen MichaelChief Executive Officer | Bought | 250 | $1.9K |
| August 25, 2026 | Heltzen MichaelChief Executive Officer | Bought | 250 | $1.9K |
| August 25, 2026 | Heltzen MichaelChief Executive Officer | Bought | 100 | $750 |
| August 19, 2026 | Heltzen MichaelChief Executive Officer | Received as pay | 8,841 | $56.6K |
| August 19, 2026 | Korman Tyler PazChief Scientific Officer | Exercised options | 32,964 | - |
| August 19, 2026 | Perriman Damien AlanChief Commercial Officer | Exercised options | 19,612 | - |
Who owns EXOZ
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
5 insiders reported holding 2,252,308 shares in total, about $9.6M at the last price.
| Holder | Shares |
|---|---|
| Korman Tyler PazChief Scientific Officer | 1,491,960 |
| Opgenorth Paul HideoVice President, Development | 645,149 |
| Perriman Damien AlanChief Commercial Officer | 91,258 |
| Heltzen MichaelChief Executive Officer | 14,453 |
| Nawaz FouadVice President- Finance | 9,488 |
Questions about EXOZ
What does Exozymes Inc. do?
Exozymes Inc. is a company in the Health care sector, listed on NASDAQ as EXOZ. Its shares trade on NASDAQ under the ticker EXOZ.
What is Exozymes Inc.'s net worth?
Exozymes Inc. has a market value (market cap) of $39.7M at the latest share price, and shareholders' equity of $3.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Exozymes Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.2M.
When did Exozymes Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the additional proxy material from September 28, 2026.
When is Exozymes Inc.'s next earnings report?
Exozymes Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EXOZ with
Follow EXOZ
Get an email when Exozymes Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Exozymes Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.